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Review Article
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Abstract: Pulmonary hypertension in left heart disease (PH-LHD) commonly complicates prolonged
heart failure (HF). When advanced, the PH becomes fixed or out of proportion and is associated with
increased morbidity and mortality in patients undergoing orthotopic heart transplant (OHT). To date, the
only recommended treatment of out of proportion PH is the treatment of the underlying HF by reducing
the pulmonary capillary wedge pressure (PCWP) with medications and often along with use of mechanical
circulatory support. Medical therapies typically used in the treatment of World Health Organization (WHO)
group 1 pulmonary arterial hypertension (PAH) have been employed off-label in the setting of PH-LHD
with varying efficacy and often negative outcomes. We will discuss the current standard of care including
treating HF and use of mechanical circulatory support. In addition, we will review the studies published
to date assessing the efficacy and safety of PAH medications in patients with PH-LHD being considered
for OHT.
Keywords: Pulmonary hypertension (PH); pulmonary hypertension-left heart disease (PH-LHD); heart failure
(HF); orthotopic heart transplant (OHT)
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Introduction
Pulmonary hypertension in left heart disease (PH-LHD)
commonly complicates prolonged heart failure (HF).
Patients undergoing orthotopic heart transplant (OHT)
with PH-LHD, and specifically out of proportion PH,
which is a combination of pre-and post-capillary PH,
have increased morbidity and mortality. An elevated
pulmonary vascular resistance (PVR) >2.5 Wood units
results in a nearly 30% increase in mortality within the first
month post-transplant (1,2). In this review, we examine
the data published between January, 1990 to present day
regarding the definition and prognosis of this disease as
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well as both medical and mechanical support therapeutic
strategies. The only guideline recommended treatment
of PH-LHD is aimed at treating the underlying HF by
reducing the pulmonary capillary wedge pressure (PCWP)
and potentially allowing the normalization of PVR over
time. These treatments for HF are well established
and include diuretics, angiotensin converting enzyme
inhibitors (ACE-I), angiotensin receptor blockers (ARBs),
mineralocorticoid receptor antagonists, ARB/neprilysin
inhibitor, beta-blockers, and in certain populations, nonspecific vasodilators such as nitrates and hydralazine. In
patients with low cardiac output, inotropic drugs may be
required. For patients with longstanding HF, mechanical
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Table 1 WHO classification of PH
WHO group

Definition

Group 1

PAH: idiopathic, heritable, drug-related, and
connective tissue PAH (such as scleroderma),
portopulmonary, HIV, schistosomiasis

Group 2

Pulmonary hypertension secondary to left heart
disease: diastolic HF, systolic HF, valvular HF

Group 3

PH due to chronic lung disease and/or chronic
hypoxemia

Group 4

Chronic thromboembolic disease

Group 5

PH which is multifactorial

WHO, World Health Organization; PH, pulmonary hypertension;
PA H , p u l m o n a r y a r t e r i a l h y p e r t e n s i o n ; H I V, h u m a n
immunodeficiency virus; HF, heart failure.

support with left ventricular assist devices (LVAD) has
demonstrated a benefit by unloading the left ventricle
(LV) and normalizing PVR, especially in candidates for
OHT (3,4).
Some medications used for the treatment of World
Health Organization (WHO) group 1 pulmonary arterial
hypertension (WHO PAH classification, Table 1) have
been employed off-label in the setting of WHO group 2
PH-LHD, perhaps driven by the hypothesis that there is
a significant PAH-like component in out of proportion
PH. These studies have demonstrated variable efficacy
and often negative outcomes in a strategy to optimize the
PVR pre-OHT. Specifically, the use of guanylyl cyclase
pathway modulators, including phosphodiesterase 5
(PDE-5) inhibitors appear to be more successful than
others, especially in the peri-operative period.
Definition of pulmonary hypertension
PH is a frequent comorbidity in patients with prolonged
HF. Nearly two thirds of patients with HF with reduced
ejection fraction (HFrEF) and HF with preserved ejection
fraction (HFpEF) have PH (5). Comorbid PH in patients
with HFrEF increases risk of HF hospital admissions and
in patients with HFpEF it is associated with an increase in
5-year all-cause mortality (6). In patients with advanced
HF, the mechanism of PH is related to a post-capillary and
passive rise in mean pulmonary artery pressure (mPAP)
resulting from a back-transmission of elevated LV diastolic
pressure (7). This type of PH is defined invasively by mPAP
>25 mmHg, and PCWP >15 mmHg, with a diastolic
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pressure gradient (DPG; defined as diastolic PA pressure—
mean PCWP) <7 mmHg (3).
In patients with prolonged HF and WHO Group 2
PH, the subtype of combined pre-and post-capillary PH,
as defined at mPAP >25 mmHg, PCWP >15 mmHg, and
DPG >7, is frequently present. In addition to the passive
rise in mPAP resulting from increased LV hydrostatic
pressures (post-capillary PH), the pre-capillary component
has characteristics of WHO group 1 PH, in which there is
vascular remodeling due to multiple pathologic changes in
biochemical signaling: a decrease in endogenous nitric oxide
(NO), increased endothelin expression, and desensitization
to natriuretic peptide induced vasodilatation (3). These
pathophysiologic mechanisms result in elevation of mPAP
in excess of PCWP, giving the names of “fixed”, “out
of proportion”, “mixed” or “combined pre-and postcapillary” PH to this disease entity. Throughout this
review we will employ the term “out of proportion” PH.
Hemodynamically, this is characterized by a PVR >5 Wood
units, transpulmonary gradient (TPG) [mPAP minus
the PCWP] >15 mmHg, non-reversible hemodynamics
by administration of pulmonary vasodilators such as
nitroprusside (8,9). Further stratification of patients with
mixed PH as those having increased or normal pulmonary
DPG may have treatment and prognostic significance, with
a DPG >7 mmHg indicating advanced pulmonary vascular
remodeling and mixed pre-and post-capillary PH (3,10,11).
PH in advanced HF and clinical outcomes
The presence of out of proportion PH has clinical and
prognostic significance for patients with longstanding HF
being considered for OHT due to elevated PVR, chronic
RV overload, and an increased risk of post-transplant right
HF. This has negatively impacted survival in the first year
post transplant (1). Current International Society for Heart
and Lung Transplantation (ISHLT) guidelines consider
PH that is not readily reversible by pulmonary vasodilators,
or “fixed PH”, to be a relative contraindication to OHT
(12-14). A review of the Cardiac Transplant Research
Database (CTRD) consisting of patient data from 26 US
institutions from the past 20 years reveals that the overall
risk of death after OHT has decreased and, in particular,
the contribution of elevated PVR to increased mortality
has declined over time from over 10% to less than 5%
at one year post transplant (15). Similar trends in postOHT outcomes are also observed from the Registry of
ISHLT (16). A reason for this important trend could be
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the result of a combination of guideline directed treatment
for Group 2 PH (4) as well as institution-specific use of
off-label Group 1 PH therapies (17) in select patients
with a normalization of PCWP on medical or mechanical
circulatory assist therapy. We will focus on the studies
to date that have examined the efficacy and outcomes of
Group 1 PH therapies in patients with Group 2 PH. Where
sufficient data is available, the discussion of treatment of
Group 2 PH will emphasize three categories of patients:
patients with HF (irrespective of presence of PH), patients
with HF and PH, and patient with HF and PH undergoing
optimization for OHT.
Treatment of PH-LHD
Vasodilators—inhaled and intravenous
Pulmonary selective vasodilators have been used for several
decades in the treatment of longstanding PH-LHD.
Their use in the acute setting has been validated by basic
and clinical science, but with no randomized controlled
studies showing a definitive benefit (18,19). These agents
act as selective pulmonary vasodilators by increasing cyclic
guanosine monophosphate resulting in an improvement
of ventilation-perfusion matching and a reduction in
PVR, although as a class there may be a less pronounced
effect on lowering TPG (17,20). Most commonly used
are inhaled nitric oxide (NO) and inhaled prostacyclins
(for example, iloprost). Both medications may be useful in
the acute peri-operative setting in patients with HF and
PH (21-23). Argenziano et al. [1998] randomized 11 of 23
consecutive patients post LVAD placement who met criteria
for elevated PVR to either NO or inhaled nitrogen therapy.
Significantly, only the 6 patients who received NO exhibited
significant reductions in mean PA pressure from 35±6 to
24±4 mmHg while the 5 patients receiving inhaled nitrogen
had no significant change in mean PA pressure (21). In a
study comparing NO and inhaled prostacyclin in post-OHT
and post lung transplant patients, both agents were found to
similarly reduce mPAP, central venous pressure and improve
cardiac index (CI) (24). In a head to head comparison of
NO and inhaled iloprost, a prostaglandin, in 46 patients
being weaned from cardiopulmonary bypass, both agents
reduced PVR, mPAP and increased cardiac output, with
the latter agent being significantly more effective (25).
Iloprost has some advantages over NO as there is no risk
of methemoglobinemia or rebound PH with prolonged use
(17,20). NO requires continuous inhalation given its very
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short half-life, with even a brief interruption resulting in
rebound PH and potential RV failure. Iloprost may be given
at doses of 5–10 mcg every 3–4 h and can be weaned off
in the perioperative period (26). While current published
studies suggest a clinical benefit in the perioperative setting,
there is no evidence to support chronic therapy with inhaled
vasodilators in HF or HF with PH patients given the cost
and difficulty of administration.
Intravenous agents such as nitroglycerin and nitroprusside,
both exogenous NO donors, are commonly used in the
acute setting to assess reversibility of PH-LHD and as a
bridge therapy to more definitive treatments (17,27,28).
In a study of 33 patients with PH secondary to end-stage
HF, the use of nesiritide, a synthetic B-type natriuretic
peptide, during hospitalization for HF significantly reduced
PCWP by 31% and mPAP by 15.6% compared to pretreatment (29). Michaels et al. [2005] studied 20 patients
with HF and PH (mPA >25 mmHg): 10 with PCWP >15
mmHg and 10 with PCWP ≤15. In the patients with what
the researchers defined as post-capillary PH or PH with a
PCWP >15, nesiritide infusion for 30 minutes decreased
both the mPA pressure and PCWP, and significantly
increased the CI (30). However, the long term therapeutic
benefit of nesiritide in pre-OHT patients is uncertain.
The intravenous form of epoprostenol appears to have
benefit in selected patients in the peri- or post-transplant
period but not as long term therapy prior to transplant
while the patient has LV dysfunction. Califf et al. [1997],
in The Flolan International Randomized Survival Trial
(FIRST), enrolled 471 patients with New York Heart
Association (NYHA) class IIIB or IV HF. With the use
of intravenous epoprostenol, hemodynamic factors such
as mPAP, PCWP, and PVR improved acutely however
the long-term infusion not only failed to demonstrate
clinical benefits but also showed a trend toward increased
mortality (31).
PDE-5 inhibitors and guanylyl cyclase agonists
The modulators of the guanylyl cyclase pathway in the
endothelium have overall shown the greatest promise of
treatment efficacy for PH-LHD. Redfield et al. [2013]
studied the effect of sildenafil, a PDE-5 inhibitor on
exercise capacity in 216 patients with HFpEF (EF >50%).
The patients were randomized to receive either sildenafil
or placebo for a total of 24 weeks. At 24 weeks peak oxygen
consumption and change in 6-minute walk test were not
significantly different between the two groups (32). Several
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randomized trials are completed or currently underway
studying the treatment efficacy of PDE-5 inhibitors in the
PH-LHD population (Table 2). Within the same general
class of guanylyl cyclase modulator therapies, novel guanylyl
cyclase stimulators are showing promise. Riociguat is a
soluble guanylate cyclase stimulator which demonstrated
positive hemodynamic effects in 2 randomized trials by
Bonderman et al. (2013 and 2014) in patients with HF and
secondary PH. Although neither trial met the primary
endpoint of change in mPAP, riociguat treatment did result
in an increase in CI, stroke volume and decrease in systemic
and peripheral vascular resistance (Table 2) (37,38).
A study by Lewis et al. [2007] in patients with HF and PH
demonstrated that the PDE-5 inhibitor sildenafil improved
NYHA class, 6-minute walk distance, as well as significantly
reduced hospitalizations for HF (40). In a retrospective
study by de Groote et al. [2015] sildenafil use pre-OHT in
18 patients resulted in a change in PVR at an average of 8.7
months of treatment from 5.3±1.9 Wood units to 3.3±1.8
Wood units (P=0.01). Five patients were able to proceed
with successful OHT and 6 with left ventricular assist
device (LVAD). All patients with a PVR <3 Wood units
after treatment survived, with survival in the group with
PVR >3 being only 44% (41). In addition, hemodynamic
parameters such as RV ejection fraction, PVR, and peak
oxygen consumption improved in this population of HF
patients with WHO group 2 PH with the administration of
sildenafil (41). The effect of sildenafil to optimize the PVR
in 119 consecutive patients was studied at one institution
by Pons et al. [2012]. Fifteen patients with a PVR >2.5
Wood units and/or TPG >12 were treated with sildenafil
pre-operatively with a target dose of 109±42 mg/day
of sildenafil (titrated and administered as three times a day
dosing) for 163±116 days prior to OHT. Hemodynamic
parameters improved in these patients: mPAP, PVR, and
TPG all decreased significantly in this group at risk for
right HF post-OHT. Specifically, mPAP decreased from
43.9±12.5 to 33.4±5.8 mmHg and PVR decreased from
5±1.1 to 3±1.6 (P<0.01) Wood units in the 15 patients
treated with sildenafil pre-operatively. Post-OHT mortality
was comparable between the two groups of patients with
and without severe PH-LHD in 6 month follow-up (42).
Endothelin receptor antagonists (ERAs)
Endothelin is a potent endogenous vasoconstrictor with
both pulmonary and systemic effects. It is upregulated
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in patients with prolonged HF and correlates with more
severe PH, increased PVR, and worse survival outcomes.
Preclinical and small clinical studies of ERA have shown
improvements in hemodynamic parameters and morbidity.
Administration of the non-specific endothelin receptor A
and B (ETA and ETB) antagonist, bosentan, in a study of
more than 80 end-stage HF patients, increased by 20%
the number of eligible patients for OHT by reducing
mPAP, PVR and TPG, as compared to the control group.
One-year survival on the transplant waiting list was also
significantly improved in this study (43). Despite initial
encouraging results, randomized trials of a non-selective
ERA, tezosentan, studied in the Randomized Intravenous
Tezosentan (RITZ) trial and the Value of Endothelin
Receptor Inhibition with Tezosentan in Acute Heart Failure
Study (VERITAS) trial have failed to show lasting positive
effect on outcomes and clinical symptoms in patients
with advanced HF (44-48). The Endothelin Antagonist
Bosentan for Lowering Cardiac Events in Heart Failure
(ENABLE) trial studied 1,000 patients with NYHA IIIB
and IV treated with low-dose bosentan did not show
differences in the primary endpoint of all-cause mortality
and HF hospitalization (49). In fact, one study reported a
high incidence of liver abnormalities (50). Non-randomized
studies of selective ETA receptor antagonists darusentan
and sitaxsentan in patients with HFrEF have demonstrated
improved hemodynamics without substantial side effects
(51,52). However, in the Endothelin A Receptor Antagonist
Trial in Heart Failure (EARTH) trial, darusentan did not
provide a sustainable benefit on LV remodeling, morbidity
or mortality in 642 patients with chronic HF (53). Due
to the overall negative results from larger, randomized
trials, the guidelines do not recommend use of the ERAs
in patients with HF and PH (4,5,12). A randomized
trial evaluating the safety and tolerability of macitentan,
another non-specific ERA, in patients with Group 2 PH
from HrEF is currently underway (54). Newer ERAs
including ambrisentan and macitentan may have a better
hepatic safety profile than bosentan and sitaxsentan, and it
is unclear if there will be a role for these drugs in patients
listed for OHT in the optimization of their PVR and TPG
pre-transplant. One common class side-effect of ERAs is
volume retention, which may complicate the treatment
of HF. Additionally, it is unclear if these PAH specific
medications would have a better safety profile and outcome
if the patients were closely monitored with pulmonary
artery catheters, ensuring their PCWP was <15 mmHg
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Table 2 Summary of randomized controlled trials of PDE-5 inhibitors and guanylyl cyclase agonists in patients with PH-LHD
Study name

Drug/author/year

Patients

Primary endpoint

Sil-HF, NCT01616381 Sildenafil/Stavanger/2012
(33)

HFrEF,
120

Patient global assessment; 6-minute Ongoing study
walk test at baseline, 8 and 24
weeks

ULTIMATE-SHF,
NCT01646515 (34)

Udenafil/Kim/2012

HFrEF, 41

VO2max with cardiopulmonary exercise Not reported
test

RELAX,
NCT00763867 (32)

Sildenafil/Redfield/2013

HFpEF,
216

Change in peak oxygen consumption No statistically significant
after 24 weeks of therapy
difference between treatment
and placebo groups

PITCH-HF,
NCT01910389 (35)

Tadalafil/Semigram/2013

HFrEF, 23

Composite outcome of CV mortality
or HF hospitalization

Not reported

Sildenafil/Fernandes/2015 (36)

HFrEF, 35

RV function, measured by CMR

No statistically significant
change in parameters; no
improvement in left ventricular
parameters or in the fractional
area change of the pulmonary
artery

LEPHT (37)

Riociguat/Bonderman/2013

HFrEF,
201

Placebo-corrected change from
baseline at week 16 in mPAP

Primary endpoint not met;
secondary endpoints: increase
in cardiac index, decrease in
PVR and SVR

DILATE-1 (38)

Riociguat/Bonderman/2014

HFpEF, 36 mPAP at rest

Primary endpoint not met;
secondary endpoints:
increased stroke volume,
decreased systolic blood
pressure and right ventricular
end-diastolic area

DYNAMIC,
NCT02744339 (39)

Riociguat/Bonderman/2016

HFpEF,
114

Ongoing study

Change from baseline of cardiac
output at rest, measured by right
heart catheterization after 26 weeks
of study drug treatment

Results

PH-LHD, pulmonary hypertension-left heart disease; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HFpEF, heart
failure with preserved ejection fraction; mPAP, mean pulmonary arterial pressure; PVR, pulmonary vascular resistance; SVR, systemic
vascular resistance; CMR, cardiovascular magnetic resonance; CV, cardiovascular.

during the use of off-label PAH medication.
Phosphodiesterase 3 (PDE3) inhibitors
PDE3 inhibitors such as milrinone and enoximone
cause direct vasodilation in the pulmonary and systemic
circulation, predominantly increasing flow with smaller
changes in TPG (17). Despite these nearly instantaneous
hemodynamic effects, this class of medications has not been
shown to improve clinical outcomes, and, in fact, increases
mortality in HF patients. Two large randomized trials with
a combined >1,000 patients [The Prospective Randomized
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Milrinone Survival Evaluation (PROMISE) and The
Studies of Oral Enoximone Therapy in Advanced Heart
Failure (ESSENTIAL)] did not show benefit of these agents
in patients with NYHA class III-IV HF (55,56). In addition,
neither of these studies included patients listed for OHT.
Combination of medical therapy and mechanical
support
A number of patients with medically refractory PHLHD have improved outcomes with the use of mechanical
circulatory support. Seventy percent of this group are
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successfully bridged to transplant and their clinical outcomes
and survival are comparable at 30 days and 12 months
to patients without out of proportion PH (12,57,58).
Hemodynamic improvement is seen early after implant
with mPAP and PVR decreasing significantly within days
(58-62). Kutty et al. [2013] demonstrated these
hemodynamic changes in their study of 29 patients
implanted with centrifugal LVADs. Baseline and post-VAD
pulmonary hemodynamics were significantly improved.
TPG was reduced from 14±3.9 to 9±3.3 mmHg and PVR
decreased from 5±1.5 to 2.1±0.5 Wood units (P<0.05)
post LVAD (58). These hemodynamic effects were also
observed by John et al. [2010], in a cohort of 50 patients
who received a continuous-flow HeartMate II LVAD.
Mean PVR decreased significantly from a baseline of
3.6±1.9 to 2.1±0.8 Wood units (P<0.001) (59). Etz et al.
[2007] demonstrated not only improvement in post-VAD
pulmonary hemodynamics but in addition more than half of
the patients were successfully bridged to OHT (63). Mikus
et al. followed 145 patients, studying the hemodynamic
effects of circulatory support from time of implant to
beyond 1 year. 56 patients had out of proportion PH, with a
baseline PVR of 3.49±1.47 Woods units, which after LVAD
support was reduced to 1.4±0.7 and 1.7±0.6 Wood units,
at 6 and 12 months, respectively (60). There are currently
no randomized clinical trials looking at the combined use
of WHO group 1 PH medical therapies and LVAD in
patients with out of proportion PH being optimized for
OHT. Recent data suggest a benefit with the concomitant
use of PDE-5 inhibitors, in particular sildenafil. In the
perioperative setting, using sildenafil improves pulmonary
hemodynamics and significantly increases cardiac
output (64). Post LVAD implantation, weaning vasodilators
such as NO could be challenging due to the side-effects of
rebound PH and decreased RV function. With the addition
of sildenafil, all patients in the study by Klodell et al. [2007]
were weaned off NO and inotropic therapies. A lasting
reduction in PA systolic pressure was observed as early as 90
minutes after the administration of oral sildenafil (65). More
than 40% of the patients in a study by Tedford et al. [2008]
had reduced PVR <3–3.5 Wood units with the combination
of LVAD and sildenafil therapy, allowing them to become
OHT candidates (66).
There are less published data on the effectiveness of
inhaled vasodilators and ERA post-LVAD and prior to
OHT. A small study of 7 patients post-LVAD demonstrated
that administering NO and iloprost significantly reduced
PVR, mPAP, RV systolic pressure, PCWP, and improved

© Journal of Thoracic Disease. All rights reserved.

2645

the efficiency of the assist device by increasing LVAD flow
within 2 h after the initiation of these medications. In all
seven patients, RVAD was avoided (67). In another study of
bosentan, 50 consecutive patients were treated post LVAD.
About 20% had to discontinue the medication because of
side effects and the rest of the patients completed the study
and had significant improvement in hemodynamics (68).
Further studies are under way to explore the use of ERAs
in patients with pre-existing PH-LHD and subsequently
normalized PCWP, as is the case in post-LVAD or OHT.
One such study which is enrolling will examine the efficacy
and safety of macitentan in patients with PH after VAD in
patients with RV failure (69).
Conclusions
PH-LHD remains a significant risk factor for morbidity
and mortality in patients being evaluated for OHT. A
standardized classification and definition of the disease
is still lacking, adding additional complexity for patient
assessment and development of studies to assess treatment
efficacy and safety. The sub-type of out of proportion PHLHD is difficult to treat and is associated with the worst
patient outcomes. Several medical therapies mostly used in
the treatment of WHO Group 1 PH have been used offlabel in the treatment of PH-LHD with varying success.
To date, the most promising results in this category suggest
that vasodilator therapies could be employed in the acute
and perioperative settings and modulators of the guanylyl
cyclase pathway could be used in more stable patients prior
to OHT. Based on the available data we have presented,
we propose a stepwise approach in the evaluation and
management of patients with PH-LHD being evaluated
for OHT (Figure 1). We hypothesize that there may be
a role for group 1 PH therapies in the treatment of PHLHD after normalization of PCWP whether by standard
HF medical therapy or mechanical circulatory support or
the concomitant use of both. However, given the available
evidence at this time, this review cannot justify the off-label
use of Group 1 PH medications such as PDE-5 inhibitors,
guanylyl cyclase stimulators, ERAs, or prostacyclins prior
to OHT in the treatment of PH-LHD, unless it is part of
a research protocol. The strongest evidence of treatment
of PH-LHD prior to OHT remains the use of standard
medical HF therapy and LVAD support. Future research
and randomized clinical trials are needed to increase our
understanding of the potential role of group 1 PH therapies
as an additional strategy to optimize patients with PH-

jtd.amegroups.com

J Thorac Dis 2017;9(8):2640-2649

2646

Koulova et al. Treatment of pulmonary hypertension in heart transplant candidates

Candidate for OHT

Right heart catheterization

Out-of-proportion PH: PVR >5 Woods units;
TPG >15 mmHg; mPAP >25 mmHg

PH reversible

Assess reversibility of PH
(vasodilator treatment)
PH not reversible

PH reversible

Trial of medical therapy
PH not reversible
LVAD ± Medical therapy

PH not reversible

Consider adjunct group 1 PH therapy
as part of research protocol

PH reversible
Proceed to OHT

Figure 1 Proposal for stepwise approach for diagnosis and management of PH-LHD. PH, pulmonary hypertension; TPG, transpulmonary
gradient; PVR, pulmonary vascular resistance; mPAP, mean pulmonary artery pressure; OHT, orthotopic heart transplantation.

LHD pre-OHT.
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